Completed PHASE2 INTERVENTIONAL 2-arm NCT03205033

Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy

Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy: a Randomized, Double-blind, Placebo-controlled Trial.

Sponsor: Hospital de Clinicas de Porto Alegre

Conditions Depression Genotoxicity Pain Sleep Disorders, Circadian Rhythm

Interventions Melatonin 20 MG Oral Capsule Placebo oral capsule

Updated 4 times since 2017 Last updated: Jun 28, 2017 Started: Jan 31, 2016 Primary completion: Jan 31, 2017 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Depression and Genotoxicity, this trial is completed. The trial is conducted by Hospital de Clinicas de Porto Alegre and has accumulated 4 data snapshots since 2016. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital de Clinicas de Porto Alegre

Data source: Hospital de Clinicas de Porto Alegre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.